NCT00219063已完成3 期
A 26 Week, Double-blind, Randomized, Multicenter, Parallel Group, Active-controlled Study Comparing Aliskiren to Ramipril With Optional Addition of Hydrochlorothiazide, Followed by a 4 Week Double-blind, Randomized, Placebo-controlled Withdrawal in Patients With Essential Hypertension
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 844
- 试验地点
- 1
- 主要终点
- Change from baseline in diastolic blood pressure after 26 weeks
研究概览
简要总结
To compare the aliskiren regimen versus the ramipril regimen on reduction in Blood Pressure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with essential hypertension
- •Patients who are eligible and able to participate in the study
排除标准
- •Severe hypertension
- •History or evidence of a secondary form of hypertension
- •History of Hypertensive encephalopathy or cerebrovascular accident. Other protocol-defined inclusion exclusion criteria also apply.
结局指标
主要结局
Change from baseline in diastolic blood pressure after 26 weeks
次要结局
- Change from baseline in diastolic blood pressure after 6 weeks and 12 weeks
- Change from baseline in systolic blood pressure after 26 weeks
- Change from baseline in systolic blood pressure after 6 weeks and 12 weeks
- Blood pressure control target of < 140/90 mmHg after 6, 12, and 26 weeks
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the ElderlyHypertensionNCT00368277Novartis Pharmaceuticals901
已完成
3 期
Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential HypertensionHypertensionNCT00739973Novartis Pharmaceuticals2,694
撤回
4 期
Aliskiren Study of Safety and Efficacy in Senior HypertensivesHypertensionNCT01922141Novartis Pharmaceuticals
已完成
3 期
A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders PatientsHypertensionNCT00219076Novartis504
已完成
3 期
Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe HypertensionModerate to Severe HypertensionNCT00841672Novartis485